This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimers disease or...
Incretin-based therapies may provide a novel way of treating neurodegenerative diseases in older adults by slowing down or halting disease progression. Several candidates for drug repurposing are currently being investigated.
This review summarizes the historical development, molecular design, and clinical relevance of incretin-based therapies, with particular emphasis on approved agents used in current clinical practice.
However, the adverse effects of chronic insulin prompted the research of alternative strategies, such as the novel antidiabetic drugs based on the incretin hormones glucagon-like protein-1 (GLP-1) and glucose-dependent insulinotropic Peptide (GIP).
This particular example perfectly highlights why Incretin Based Therapies For Aging Treatment is so captivating.
The current narrative review, including studies published from September 1987 to September 2025, summarized the recent improvements regarding to the incretin-based therapy for cognitive impairment associated to the type 2 diabetes mellitus.
By combining metabolic, inflammatory, and neurotrophic benefits, incretin-based drugs embody a holistic strategy that could transform patient outcomes.
